BTBP(SH:600161)2014-04-28 16:00Financial Performance - Operating revenue rose by 17.63% to CNY 457,865,327.26 from CNY 389,248,772.94 in the same period last year[11] - Net profit attributable to shareholders decreased by 1.43% to CNY 94,814,950.31, down from CNY 96,186,118.12 year-on-year[11] - The weighted average return on net assets decreased by 1.20 percentage points to 4.80%[11] - Total operating revenue for the current period reached ¥457,865,327.26, an increase of 17.6% compared to ¥389,248,772.94 in the previous period[35] - Net profit for the current period was ¥114,549,067.17, slightly up from ¥113,511,248.55 in the previous period, reflecting a growth of 0.9%[36] - Basic earnings per share for the current period was ¥0.18, compared to ¥0.19 in the previous period, indicating a decrease of 5.3%[36] Cash Flow - The net cash flow from operating activities was negative at CNY -85,582,183.02, a decline of 876.68% compared to the previous year[11] - Operating cash flow outflows totaled CNY 409,512,964.66, an increase from CNY 309,453,677.64 in the previous period, resulting in a net cash flow from operating activities of -CNY 85,582,183.02 compared to -CNY 8,762,536.31[40] - Cash flow from operating activities was ¥323,930,781.64, compared to ¥300,691,141.33 in the previous period, showing an increase of 7.7%[39] - Cash received from operating activities was CNY 50,072,725.07, down from CNY 69,107,031.74, indicating a decline in operational performance[44] - Cash paid for purchasing goods and services was CNY 30,126,102.44, compared to CNY 37,299,992.59 in the previous period[44] Assets and Liabilities - Total assets increased by 7.48% to CNY 6,056,030,788.37 compared to the end of the previous year[11] - Total assets increased to ¥5,162,598,402.45 from ¥4,854,684,402.26, representing a growth of 6.3%[32] - Total liabilities rose to ¥3,466,152,165.14, up from ¥3,191,620,421.61, marking an increase of 8.6%[32] - Accounts receivable increased to ¥260,758,074.18 from ¥144,697,660.58, reflecting a significant rise of 80.0%[32] - The company reported a total equity of ¥1,696,446,237.31, up from ¥1,663,063,980.65, indicating a growth of 2.0%[32] Investments and Financing - Cash flow from financing activities increased by 255.34% to ¥409,379,570.39, due to receiving ¥300 million in state-owned capital operating budget funds[23] - Financing cash inflows reached CNY 548,238,731.85, significantly higher than CNY 320,809,876.59, with net cash flow from financing activities of CNY 409,379,570.39 compared to CNY 115,208,587.81[42] - Investment income of ¥475,590.00 was recognized from the sale of a 30% stake in Tianjin Rongsheng Pharmaceutical Co., Ltd.[24] - Cash inflows from financing activities included CNY 603,728,396.72 from borrowings, compared to CNY 293,000,000.00 in the previous period[46] Operational Changes - Management expenses increased by 107.44% year-on-year, totaling ¥97,217,940.69, primarily due to relocation costs and increased technical consulting fees[22] - The company recognized government subsidies of CNY 1,392,732.28, primarily for research support[13] - The company plans to continue expanding its market presence and enhance its product offerings in the upcoming quarters[20] - The company reported a decrease in accounts receivable due to reduced sales receipts[20] Other Financial Metrics - Cash flow from investing activities decreased by 10.40% to -¥168,753,016.03, reflecting increased investment in the Yizhuang vaccine industrial base project[23] - Cash received from investment activities totaled CNY 11,871,916.66, a decrease from CNY 14,250,250.00[45] - Cash paid for fixed assets and other long-term assets was CNY 153,220,013.03, slightly up from CNY 138,134,589.60[45] - Other non-current assets rose by 57.94% to ¥304,180,221.02, indicating strategic investments[22]